LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Neoplasm Metastasis
Trial Timeline
Dec 22, 2025 → May 1, 2033
NCT ID
NCT07174336About LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant is a phase 3 stage product being developed by Eli Lilly for Breast Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07174336. Target conditions include Breast Neoplasms, Neoplasm Metastasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07174336 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Neoplasms